# A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects

> **NCT01920399** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CAZ-AVI
- **DRUG:** 0.9% Normal Saline

## Key facts

- **NCT ID:** NCT01920399
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920399, "A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01920399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*